Broad variation in response of individual introns to splicing inhibitors in a humanized yeast strain
Open Access
- 28 November 2023
- journal article
- research article
- Published by Cold Spring Harbor Laboratory in RNA
- Vol. 30 (2) , 149-170
Abstract
Intron branchpoint (BP) recognition by the U2 snRNP is a critical step of splicing, vulnerable to recurrent cancer mutations and bacterial natural product inhibitors. The BP binds a conserved pocket in the SF3B1 (human) or Hsh155 (yeast) U2 snRNP protein. Amino acids that line this pocket affect the binding of splicing inhibitors like Pladienolide-B (Plad-B), such that organisms differ in their sensitivity. To study the mechanism of splicing inhibitor action in a simplified system, we modified the naturally Plad-B resistant yeastSaccharomyces cerevisiaeby changing 14 amino acids in the Hsh155 BP pocket to those from human. This humanized yeast grows normally, and splicing is largely unaffected by the mutation. Splicing is inhibited within minutes after the addition of Plad-B, and different introns appear inhibited to different extents. Intron-specific inhibition differences are also observed during cotranscriptional splicing in Plad-B using single-molecule intron tracking to minimize gene-specific transcription and decay rates that cloud estimates of inhibition by standard RNA-seq. Comparison of Plad-B intron sensitivities to those of the structurally distinct inhibitor Thailanstatin-A reveals intron-specific differences in sensitivity to different compounds. This work exposes a complex relationship between the binding of different members of this class of inhibitors to the spliceosome and intron-specific rates of BP recognition and catalysis. Introns with variant BP sequences seem particularly sensitive, echoing observations from mammalian cells, where monitoring individual introns is complicated by multi-intron gene architecture and alternative splicing. The compact yeast system may hasten the characterization of splicing inhibitors, accelerating improvements in selectivity and therapeutic efficacy.Keywords
All Related Versions
Funding Information
- National Institutes of Health (R01 GM040478, R35 GM145266)
- Jane Coffin-Childs postdoctoral fellowship and a UC President's Postdoctoral Fellowship
This publication has 96 references indexed in Scilit:
- STAR: ultrafast universal RNA-seq alignerBioinformatics, 2012
- Quality control of MAT a1 splicing and exon skipping by nuclear RNA degradationNucleic Acids Research, 2011
- Reduced fidelity of branch point recognition and alternative splicing induced by the anti-tumor drug spliceostatin AGenes & Development, 2011
- The anti-tumor drug E7107 reveals an essential role for SF3b in remodeling U2 snRNP to expose the branch point-binding regionGenes & Development, 2011
- Dynamic transcriptome analysis measures rates of mRNA synthesis and decay in yeastMolecular Systems Biology, 2011
- Spliceostatin A inhibits spliceosome assembly subsequent to prespliceosome formationNucleic Acids Research, 2010
- Invariant U2 snRNA Nucleotides Form a Stem Loop to Recognize the Intron Early in SplicingMolecular Cell, 2010
- Yeast Pre-rRNA Processing and Modification Occur CotranscriptionallyMolecular Cell, 2010
- Competition between the ATPase Prp5 and Branch Region-U2 snRNA Pairing Modulates the Fidelity of Spliceosome AssemblyMolecular Cell, 2007
- A versatile toolbox for PCR‐based tagging of yeast genes: new fluorescent proteins, more markers and promoter substitution cassettesYeast, 2004